edoc

Safety and differential antibody and T-cell responses to Plasmodium falciparum sporozoite vaccine by age in Tanzanian adults, adolescents, children, and infants

Jongo, Said A. and Church, L. W. Preston and Mtoro, Ali T. and Chakravarty, Sumana and Ruben, Adam J. and Swanson, Phillip A. and Kassim, Kamaka R. and Mpina, Maximillian and Tumbo, Anneth-Mwasi and Milando, Florence A. and Qassim, Munira and Juma, Omar A. and Bakari, Bakari M. and Simon, Beatus and James, Eric R. and Abebe, Yonas and Kc, Natasha and Saverino, Elizabeth and Gondwe, Linda and Studer, Fabian and Fink, Martina and Cosi, Glenda and El-Khorazaty, Jill and Styers, David and Seder, Robert A. and Schindler, Tobias and Billingsley, Peter F. and Daubenberger, Claudia and Sim, B. Kim Lee and Tanner, Marcel and Richie, Thomas L. and Abdulla, Salim and Hoffman, Stephen L.. (2019) Safety and differential antibody and T-cell responses to Plasmodium falciparum sporozoite vaccine by age in Tanzanian adults, adolescents, children, and infants. American journal of tropical medicine and hygiene, 100 (6). pp. 1433-1444.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/71187/

Downloads: Statistics Overview

Abstract

In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria's impact. Sanaria; ®; PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved; Plasmodium falciparum; (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria-naïve and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the United States and field transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore, evaluated PfSPZ Vaccine in 93 Tanzanians aged 45 years to 6 months in a randomized, double-blind, normal saline placebo-controlled trial. There were no significant differences in adverse events between vaccinees and controls or between dosage regimens. Because all age groups received three doses of 9.0 × 10; 5; PfSPZ of PfSPZ Vaccine, immune responses were compared at this dosage. Median antibody responses against Pf circumsporozoite protein and PfSPZ were highest in infants and lowest in adults. T-cell responses were highest in 6-10-year olds after one dose and 1-5-year olds after three doses; infants had no significant positive T-cell responses. The safety data were used to support initiation of trials in > 300 infants in Kenya and Equatorial Guinea. Because PfSPZ Vaccine-induced protection is thought to be mediated by T cells, the T-cell data suggest PfSPZ Vaccine may be more protective in children than in adults, whereas infants may not be immunologically mature enough to respond to the PfSPZ Vaccine immunization regimen assessed.
Faculties and Departments:03 Faculty of Medicine > Departement Public Health > Sozial- und Präventivmedizin > Malaria Vaccines (Tanner)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Health Interventions > Malaria Vaccines (Tanner)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Clinical Immunology (Daubenberger)
UniBasel Contributors:Mpina, Maximillian and Tumbo, Anneth and Gondwe, Linda and Schindler, Christian and Daubenberger, Claudia and Tanner, Marcel
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Williams and Wilkins
ISSN:0002-9637
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:10 Jul 2019 13:38
Deposited On:10 Jul 2019 13:38

Repository Staff Only: item control page